The host control of lytic and latent infection with human herpesvirus-8

Journal of Infectious Diseases

Volumn 193, Issue 8, 2006, Pages 1051-1053

  Stebbing, Justin ^a   Gazzard, Brian ^a   Bower, Mark ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS ANTIGEN; CYTOKINE; HLA ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 12A; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 6; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBODY DETECTION; ANTIBODY PRODUCTION; DNA SEQUENCE; EDITORIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE LOCUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INCIDENCE; INFECTION CONTROL; INFECTION RISK; INFECTION SENSITIVITY; KAPOSI SARCOMA; LATENT VIRUS INFECTION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REMISSION; VIRUS CELL INTERACTION; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CYTOKINES; HERPESVIRUS 8, HUMAN; HIV INFECTIONS; HUMANS; IMMUNOGENETICS; SARCOMA, KAPOSI;

EID: 33645753487     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/501475     Document Type: Editorial

References (28)

1. Brown EE, Fallin MD, Goedert JJ, et al. Host immunogenetics and control of human herpesvirus-8 infection. J Infect Dis 2006; 193:1054-62 (in this issue).
2. Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med 1997; 337:1485-90.
3. Louie T. Occupational hazards. N Engl J Med 2005; 353:757-9.
4. Stebbing J, Gazzard B, Flore O, et al. Natural killer cells are not infected by Kaposi's sarcoma-associated herpesvirus in vivo, and natural killer cell counts do not correlate with the risk of developing Kaposi's sarcoma. AIDS 2003; 17:1998-2000.
5. Stebbing J, Gazzard B, Mandalia S, et al. Antiretroviral treatment regimens and immuneparameters in the prevention of systemic AIDS-related non-Hodgkin's lymphoma. J Clin Oncol 2004; 22:2177-83.
6. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60.
7. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000; 92:1823-30.
8. Andreoni M, Goletti D, Pezzotti P, et al. Prevalence, incidence and correlates of HHV-8/KSHV infection and Kaposi's sarcoma in renal and liver transplant recipients. J Infect 2001; 43:195-9.
9. Emond JP, Marcelin AG, Dorent R, et al. Kaposi's sarcoma associated with previous human herpesvirus 8 infection in heart transplant recipients. J Clin Microbiol 2002; 40:2217-9.
10. Zmonarski SC, Boratynska M, Puziewicz-Zmonarska A, Kazimierczak K, Klinger M. Kaposi's sarcoma in renal transplant recipients. Ann Transplant 2005; 10:59-65.
11. Langford A, Ruf B, Kunze R, Pohle HD, Reichart P. Regression of oral Kaposi's sarcoma in a case of AIDS on zidovudine (AZT). Br J Dermatol 1989; 120:709-13.
12. Bower M, Nelson M, Young AM, et al. Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma. J Clin Oncol 2005; 23:5224-8.
13. Albini A, Soldi R, Giunciuglio D, et al. The angiogenesis induced by HIV-1 Tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells. Nat Med 1996; 2:1371-5.
14. Deregibus MC, Cantaluppi V, Doublier S, et al. HIV-1-Tat protein activates phosphatidylinositol 3-kinase/AKT-dependent survival pathways in Kaposi's sarcoma cells. J Biol Chem 2002; 277:25195-202.
15. Ensoli B, Barillari G, Salahuddin SZ, Gallo RC, Wong-Staal F. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature 1990; 345:84-6.
16. Albini A, Benelli R, Presta M, et al. HIV-tat protein is a heparin-binding angiogenic growth factor. Oncogene 1996; 12:289-97.
17. Barnett SVV, Murthy KK, Herndier BG, Levy JA. An AIDS-like condition induced in baboons by HIV-2. Science 1994; 266:642-6.
18. Varthakavi V, Smith RM, Deng H, Sun K, Spearman P. Human immunodeficiency virus type-1 activates lytic cycle replication of Kaposi's sarcoma-associated herpesvirus through induction of KSHV Rta. Virology 2002; 297:270-80.
19. Harrington W Jr, Sieczkowski L, Sosa C, et al. Activation of HHV-8 by HIV-1 tat. Lancet 1997; 349:774-5.
20. Sgadari C, Barillari G, Toschi E, et al. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med 2002; 8:225-32.
21. Stebbing J, Wildfire A, Portsmouth S, et al. Paclitaxel for anthracycline-resistant AIDS-related Kaposi's sarcoma: clinical and angiogenic correlations. Ann Oncol 2003; 14:1660-6.
22. Woolfson A, Stebbing J, Tom BD, et al. Conservation of unique cell-surface CD antigen mosaics in HIV-1-infected individuals. Blood 2005; 106:1003-7.
23. Ingman M, Kaessmann H, Paabo S, Gyllensten U. Mitochondrial genome variation and the origin of modern humans. Nature 2000; 408:708-13.
24. Fujiyama A, Watanabe H, Toyoda A, et al. Construction and analysis of a human-chimpanzee comparative clone map. Science 2002; 295:131-4.
25. de Groot NG, Otting N, Doxiadis GG, et al. Evidence for an ancient selective sweep in the MHC class 1 gene repertoire of chimpanzees. Proc Natl Acad Sci USA 2002; 99:11748-53.
26. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42.
27. Holmes KV. SARS-associated coronavirus. N Engl J Med 2003; 348:1948-51.
28. Beigel JH, Farrar J, Han AM, et al. Avian influenza A (H5N1) infection in humans. N Engl J Med 2005; 353:1374-85.